Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands
- 26 February 2020
- journal article
- research article
- Published by Springer Nature in Nature Protocols
- Vol. 15 (4) , 1507-1524
Abstract
The expression of synthetic receptors in primary T cells enables the programming of user-defined responses when designing T-cell therapies. Chimeric antigen receptors (CARs) are synthetic receptors that have demonstrated efficacy in cancer therapy by targeting immobilized antigens on the surface of malignant cells. Recently, we showed they can also rewire T-cell responses to soluble ligands. In contrast to other synthetic receptors, CARs are not only readily engineered by rational design, but also clinically translatable, with robust function in primary human T cells. This protocol discusses design principles for CARs responsive to soluble ligands and delineates steps for producing T cells expressing synthetic receptors. Functional assays for quantifying the ability of CAR T cells to sense and respond to soluble ligands are also presented. This protocol provides a framework for proficient immune-cell researchers to test novel T-cell therapies targeting soluble ligands in <2 weeks.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP5OD012133)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U54HL119893)
- U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR001881)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30CA183528)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM067555)
This publication has 32 references indexed in Scilit:
- Outsmarting and outmuscling cancer cells with synthetic and systems immunologyCurrent Opinion in Biotechnology, 2019
- TGF‐β–responsive CAR‐T cells promote anti‐tumor immune functionBioengineering & Translational Medicine, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Rewiring T-cell responses to soluble factors with chimeric antigen receptorsNature Chemical Biology, 2018
- Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic CancerMolecular Therapy, 2017
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaScience Translational Medicine, 2015
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine ReceptorMolecular Therapy, 2014
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011